FDA-approved dual GIP/GLP-1 receptor agonist with superior weight loss efficacy vs semaglutide in head-to-head data.
Tirzepatide is the first commercially available dual agonist of both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, developed by Eli Lilly and approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The addition of GIP activity is what differentiates tirzepatide from single-agonist GLP-1s like semaglutide — and is thought to explain its superior efficacy, with the SURMOUNT-1 trial showing ~22.5% mean body weight reduction at 72 weeks at the maintenance dose.
Head-to-head, tirzepatide has outperformed semaglutide on weight, HbA1c, and lipid endpoints. The cardiovascular outcomes data is still maturing, but metabolic biomarkers move in the same favorable directions — often with steeper magnitude. Most users who have tried both report a different subjective experience: tirzepatide tends to feel "cleaner" in terms of appetite reduction, with somewhat less overt nausea profile for many.
Because the titration runs longer (up to 6 steps vs 5), and doses go higher (up to 15 mg vs 2.4 mg), the protocol decisions around tirzepatide are more nuanced. Tracking the right biomarkers on a cadence that captures the curve — not just endpoints — is where the value of a structured tracking tool really shows.
Tirzepatide binds and activates both the GIP and GLP-1 receptors. GLP-1 activity produces glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, and appetite reduction. GIP activity adds additional insulinotropic effect and has been shown to modulate adipose tissue function, potentially improving the quality of weight loss (higher fat-to-lean ratio). The synergy between the two pathways is thought to be non-additive — more than the sum of its parts.
Standard titration per label: 2.5 mg weekly × 4 weeks, increasing in 2.5 mg steps every 4 weeks to 10–15 mg maintenance. Many users hold at 5 mg or 7.5 mg for extended periods if response is adequate. Compounded versions are common through 503A pharmacies. Critical tracking: HbA1c at baseline + 3 months + 6 months, lipid panel (with ApoB) quarterly, weight weekly, and any GI side effects logged against dose changes.
Education only — not medical advice. Any protocol change should involve your licensed provider.
When running Tirzepatide, these are the biomarkers most commonly tracked to assess response and safety:
Free calculator for Tirzepatide reconstitution math — vial size, BAC water volume, and exact syringe units.
Open Tirzepatide calculator →Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.
Start tracking →This page is informational and does not constitute medical advice. MyProtocolStack is a tracking and education platform. Work with a licensed provider before starting, changing, or stopping any protocol.